An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®). "ROSE"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- age 18 years or above after study start
- index date on or after study start
- signed, informed consent
- patients treated for DVT or PE
- patients with non-valvular AF (with one or more risk factors) treated for prevention of stroke and systemic embolism

Exclusion Criteria

- any use of univalent direct thrombin inhibitor or direct factor Xa inhibitors
- use of anticoagulant therapy or other vitamin K antagonists recorded within one year prior to index date